Sector
PharmaceuticalsOpen
₹6,140Prev. Close
₹6,096.2Turnover(Lac.)
₹43,178.44Day's High
₹6,192.95Day's Low
₹6,105.152 Week's High
₹6,285.4552 Week's Low
₹3,350Book Value
₹543.65Face Value
₹2Mkt Cap (₹ Cr.)
1,62,752.15P/E
88.09EPS
69.2Divi. Yield
0.49EBITDA reached ₹716 crore for the quarter, marking a 49.5% rise compared to ₹479 crore in Q2 2023.
Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.
The company's first-quarter earnings before interest, taxes, depreciation, and amortisation (EBITDA) were ₹622 Crore.
Here are some of the stocks that may see significant price movement today: Ashoka Buildcon, JSW Steel, Ambuja Cements, etc.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 53 | 53 | 53.09 | 53.09 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 13,431 | 12,652 | 11,638.26 | 9,218.48 |
Net Worth | 13,484 | 12,705 | 11,691.35 | 9,271.57 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 8,879.82 | 6,798.61 | 5,310.57 | 3,815.94 |
yoy growth (%) | 30.61 | 28.02 | 39.16 | -5.16 |
Raw materials | -2,989.8 | -2,265.5 | -2,088.56 | -1,504.9 |
As % of sales | 33.66 | 33.32 | 39.32 | 39.43 |
Employee costs | -926.55 | -808.68 | -608.36 | -446.27 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 3,676.52 | 2,627.87 | 1,813.29 | 1,219.36 |
Depreciation | -310.55 | -254.65 | -185.95 | -142.42 |
Tax paid | -727.98 | -673.15 | -440.58 | -349.78 |
Working capital | 2,090.79 | 2,216.26 | 733.27 | 298.91 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 30.61 | 28.02 | 39.16 | -5.16 |
Op profit growth | 37.42 | 55.37 | 45.16 | -13.01 |
EBIT growth | 39.89 | 44.47 | 49.04 | -12.21 |
Net profit growth | 50.84 | 42.39 | 57.85 | -17.43 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 7,845 | 7,767 | 8,959.83 | 6,969.4 | 5,394.42 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 7,845 | 7,767 | 8,959.83 | 6,969.4 | 5,394.42 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 339 | 345 | 113.87 | 62.56 | 189.63 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,804.85 | 157.5 | 4,34,195.65 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,130.75 | 88.09 | 1,61,829.65 | 518 | 0.49 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,477.4 | 28.59 | 1,21,053.04 | 1,178.16 | 0.87 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,332.5 | 69.57 | 1,13,812.4 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,586.45 | 52.35 | 1,04,937.42 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Murali K Divi
Executive Director
N V Ramana
Whole Time Director & CEO
Kiran S Divi
Independent Director
K V K Seshavataram
Chairman & Independent Directo
Ramesh B V Nimmagadda
Whole Time Director -Commercia
Nilima Motaparti
Independent Director
S Ganapaty
Independent Director
Sunaina Singh
Independent Director
Kosaraju Veerayya Chowdary
Company Sec. & Compli. Officer
Satish Choudhury
Whole-time Director
S. Devendra Rao
Independent Director
Rajendrakumar Premchand Shah
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Divis Laboratories Ltd
Summary
Divis Laboratories Ltd. is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the worlds largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (APIs), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. It is among the largest pharmaceutical companies in India with a portfolio of approx. 160 products across diverse therapeutic areas. Presently, it has 6 manufacturing facilities and market presence across several countries. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divis Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale proc
Read More
The Divis Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹6130.75 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Divis Laboratories Ltd is ₹162752.15 Cr. as of 06 Dec ‘24
The PE and PB ratios of Divis Laboratories Ltd is 88.09 and 11.87 as of 06 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Divis Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Divis Laboratories Ltd is ₹3350 and ₹6285.45 as of 06 Dec ‘24
Divis Laboratories Ltd's CAGR for 5 Years at 27.61%, 3 Years at 9.47%, 1 Year at 62.95%, 6 Month at 35.39%, 3 Month at 19.05% and 1 Month at 4.90%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice